New injection targets tumors from inside out in advanced cancer trial
NCT ID NCT04260529
First seen Feb 01, 2026 · Last updated Apr 30, 2026 · Updated 8 times
Summary
This early-phase trial tested a new drug, CyPep-1, injected directly into tumors in 60 people with advanced solid cancers that had stopped responding to standard treatments. The study looked at safety and whether the drug, given alone or with the immunotherapy pembrolizumab, could shrink injected tumors and even distant ones. The goal was to find a safe dose and see early signs of tumor control, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EMC
Rotterdam, Netherlands
-
Institue Curie
Paris, France
-
Institute Gustave Roussy
Villejuif, France
-
LUMC
Leiden, Netherlands
-
NKI/AvL
Amsterdam, Netherlands
-
START
Madrid, Spain
-
UMCU
Utrecht, Netherlands
-
Vall d'Hebron (VHIO)
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.